A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia

CONTEXT: Patients with classic congenital adrenal hyperplasia (CAH) often require supraphysiologic glucocorticoid doses to suppress adrenocorticotropic hormone (ACTH) and control androgen excess. Nevanimibe hydrochloride (ATR-101), which selectively inhibits adrenal cortex function, might reduce and...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Endocrinol Metab
Autori principali: El-Maouche, Diala, Merke, Deborah P, Vogiatzi, Maria G, Chang, Alice Y, Turcu, Adina F, Joyal, Elizabeth G, Lin, Vivian H, Weintraub, Lauren, Plaunt, Marianne R, Mohideen, Pharis, Auchus, Richard J
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Clinical Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7331874/
https://ncbi.nlm.nih.gov/pubmed/32589738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/clinem/dgaa381
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi